

Haematologica
HAEMATOL/2017/175729
Version 4

Somatic STAT3 mutations in the Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia

Paula Savola, Oscar Brück, Thomas Olson, Tiina Kelkka, Markku J. Kauppi, Panu E Kovanen, Soili Kytölä, Tuulikki Sokka-Isler, Thomas P. Loughran, Marjatta Leirisalo-Repo, and Satu Mustjoki

Disclosures: S. M. has received honoraria and research funding from Novartis, Bristol-Myers Squibb, Pfizer, and Ariad. These are all unrelated to this project. M.L.-R. has received honoraria from Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, Lilly, MSD, Pfizer, Regeneron, and Roche. These are all unrelated to this project. T.O. and T.L. were supported by R01CA178393 awarded to T.L. and T.O. was supported for part of this period by T32CA009109 (National Cancer Institute of the National Institutes of Health). T. S-I has received grant/research support from Academy of Finland, Abbott, Hospira, MSD, Pfizer, and consultant/speaker fees from Abbvie, BMS, Celgene, DiaGraphIT, Eli Lilly, GSK,

Contributions: P.S., M.L-R., and S.M. designed the study. P.S., T.O., M.K., S.K., P.E.K., T.S-I., T.L., and M.L-R collected patient information and samples. P.S., O.B. and T.K. performed laboratory experiments and analyzed the data. P.S. and S.M. prepared the manuscript, and all authors contributed to the writing process and accepted the final version of the manuscript.